Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working groupCarsten Denkert, Roberto Salgado, Stephan Wienert et al.|Modern Pathology|2016Cited by 281
Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assayCarsten Denkert, Manfred Dietel, Ralf Kronenwett et al.|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2012Cited by 92
Das ER-positive, HER2-negative Mammakarzinom - Der EndoPredict®-Test hilft bei der Entscheidung über die endokrine Therapie +/- ZytostaseManfred Dietel, Carsten Denkert, Ralf Kronenwett et al.|Senologie - Zeitschrift für Mammadiagnostik und -therapie|2012Cited by 3
Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0